NCT05117346View on ClinicalTrials.gov

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Bradycardia
Interventions
DRUG

CARDIX-101A, CARDIX-101B, CARDIX-101C

Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.

Trial Locations (1)

92126

SpaceMed-X, San Diego

Sponsors
All Listed Sponsors
lead

Cardix Therapeutics LLC

INDUSTRY

NCT05117346 - An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia | Biotech Hunter | Biotech Hunter